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Abstract: BACKGROUND AND PURPOSE Clazosentan, an endothelin receptor antagonist, has been
shown to reduce vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). CONSCIOUS-3 assessed
whether clazosentan reduced vasospasm-related morbidity and all-cause mortality postaSAH secured by
endovascular coiling. METHODS This double-blind, placebo-controlled, phase III trial randomized pa-
tients with aSAH secured by endovascular coiling to ฀ 14 days intravenous clazosentan (5 or 15 mg/h) or
placebo. The primary composite end point (all-cause mortality; vasospasm-related new cerebral infarcts
or delayed ischemic neurological deficits; rescue therapy for vasospasm) was evaluated 6 weeks postaSAH.
The main secondary end point was dichotomized extended Glasgow Outcome Scale (week 12). RESULTS
CONSCIOUS-3 was halted prematurely following completion of CONSCIOUS-2; 577/1500 of planned pa-
tients (38%) were enrolled and 571 were treated (placebo, n=189; clazosentan 5 mg/h, n=194; clazosentan
15 mg/h, n=188). The primary end point occurred in 50/189 of placebo-treated patients (27%), com-
pared with 47/194 patients (24%) treated with clazosentan 5 mg/h (odds ratio [OR], 0.786; 95% CI,
0.479-1.289; P=0.340), and 28/188 patients (15%) treated with clazosentan 15 mg/h (OR, 0.474; 95%
CI, 0.275-0.818; P=0.007). Poor outcome (extended Glasgow Outcome Scale score ฀ 4) occurred in 24%
of patients with placebo, 25% of patients with clazosentan 5 mg/h (OR, 0.918; 95% CI, 0.546-1.544;
P=0.748), and 28% of patients with clazosentan 15 mg/h (OR, 1.337; 95% CI, 0.802-2.227; P=0.266).
Pulmonary complications, anemia, and hypotension were more common in patients who received cla-
zosentan than in those who received placebo. At week 12, mortality was 6%, 4%, and 6% with placebo,
clazosentan 5 mg/h, and clazosentan 15 mg/h, respectively. CONCLUSIONS Clazosentan 15 mg/h
significantly reduced postaSAH vasospasm-related morbidity/all-cause mortality; however, neither dose
improved outcome (extended Glasgow Outcome Scale).
DOI: https://doi.org/10.1161/STROKEAHA.111.648980
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Abstract 
Word count: 250 (250 words maximum) 
Background and purpose: Clazosentan, an endothelin receptor antagonist, has been shown to 
reduce vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). CONSCIOUS-3 assessed 
whether clazosentan reduced vasospasm-related morbidity and all-cause mortality after aSAH 
secured by endovascular coiling. 
Methods: This double-blind, placebo-controlled, phase III trial randomized patients with aSAH 
secured by endovascular coiling to receive intravenous clazosentan (5 or 15mg/h) or placebo for ≤14 
days. The primary composite endpoint (all-cause mortality; new cerebral infarcts; delayed ischemic 
neurological deficit due to vasospasm; rescue therapy for vasospasm) was evaluated 6-weeks post-
aSAH and reviewed centrally by a blinded critical events committee. The main secondary endpoint 
was the extended Glasgow Outcome Scale (GOSE; dichotomized, week 12). 
Results: CONSCIOUS-3 was halted prematurely following non-significant results from CONSCIOUS-
2; 577/1,470 (39%) of the planned patients were enrolled and 571 treated (placebo n=189, 
clazosentan 5mg/h n=194, clazosentan 15mg/h n=188). The primary endpoint occurred in 27% of 
placebo-treated patients, compared with 24% treated with clazosentan 5mg/h (odds ratio [OR]= 
0.786, P=0.340), and 15% treated with clazosentan 15mg/h (OR=0.474, P=0.007). Poor functional 
outcome (GOSE score ≤4) occurred in 24% (placebo), 25% (clazosentan 5mg/h; P=0.748), and 28% 
(clazosentan 15mg/h; P=0.266) of patients. Pulmonary complications, anemia, and hypotension were 
more common in patients receiving clazosentan than placebo. At week 12, mortality rates were 6.3%, 
3.6% and 6.4% with placebo, clazosentan 5 and 15mg/h, respectively. 
Conclusions: Clazosentan at 15mg/h significantly reduced vasospasm-related morbidity/all-cause 
mortality after aSAH; the effect with clazosentan 5mg/h was not significant. Neither dose improved 
functional outcome (GOSE).  
Clinical trial registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00940095 
[Note, the wording relating to clinical trial registration is a journal requirement] 
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Introduction 
Cerebral vasospasm is the leading cause of mortality and disability following aneurysmal 
subarachnoid hemorrhage (aSAH).1 Of those who survive aSAH, angiographic vasospasm accounts 
for approximately 50% of deaths.2 Vasospasm also contributes to delayed ischemic neurological 
deficits (DIND) that occur in up to 40% of aSAH cases, and approximately half of patients with DIND 
develop ischemic infarctions.3 As vasospasm after aSAH is unpredictable, common, difficult to 
manage, and associated with poor long-term outcomes, prevention is a highly desired management 
strategy; prophylactic nimodipine and hemodynamic rescue therapies are widely used, although 
evidence for their efficacy is limited.2 
The pathogenesis of angiographic vasospasm includes increased levels of vasoconstrictors, such as 
endothelin 1.4,5 Clazosentan is a selective endothelin receptor antagonist, which was investigated for 
prevention of angiographic vasospasm in patients with aSAH in the phase IIb CONSCIOUS-1 
(clazosentan to overcome neurological ischemia and infarct occurring after subarachnoid 
hemorrhage) study.6 In CONSCIOUS-1, clazosentan (1, 5, and 15mg/h) produced a dose-dependent 
reduction in moderate or severe angiographic vasospasm with a 65% relative risk reduction (RRR) 
with the highest dose (p<0.0001).  
On the basis of CONSCIOUS-1, two phase III studies (CONSCIOUS-2 and CONSCIOUS-3) were 
designed to assess the effect of clazosentan on the incidence of cerebral vasospasm-related 
morbidity and all-cause mortality, and clinical outcome, in patients with aSAH and substantial 
subarachnoid blood who were at high risk of developing DIND. In CONSCIOUS-2, patients who had 
their aSAH secured by clipping received placebo or clazosentan 5mg/h; however, no effect was seen 
with active treatment.7 Use of the 15mg/h clazosentan dose in CONSCIOUS-3 was based on 
CONSCIOUS-1 study data, where the effect of clazosentan was less with 5mg/h in aSAH secured by 
coiling than by clipping.6 
CONSCIOUS-3 was initiated on 10 July 2009. The trial was halted prematurely following non-
significant results from the parallel CONSCIOUS-2 clipping study,7 and subsequent recommendations 
from the Data and Safety Monitoring Board (DSMB). A total of 577 patients, representing 39% of the 
planned 1,470 sample size, had been randomized at the time of study termination; this article reports 
outcomes for the 571 patients who received treatment. 
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Methods 
This was a phase III, prospective, multicenter, international, randomized, double-blind, placebo-
controlled trial (NCT00940095). Eligible patients were 18-75 years old with aSAH due to ruptured 
saccular aneurysm secured by endovascular coiling, with any thick clot (short axis ≥4 mm) on 
baseline computed tomographic (CT) scan, World Federation of Neurological Surgeons (WFNS) 
grades I-IV prior to coiling procedure, and able to start study drug within 56 hours of aneurysm 
rupture. Women of childbearing potential were included only following a negative pregnancy test. 
Written informed consent was obtained. 
Exclusion criteria included: giant aneurysms (height or width ≥25 mm); intraventricular or intracerebral 
blood in the absence of subarachnoid blood; vasospasm on pre-coiling angiogram; a major 
complication during coiling procedure; current ruptured aneurysm previously secured (successfully or 
not) by clipping; missing digital subtraction angiography at the end of the coiling procedure; or several 
aneurysms among which the ruptured one was not identifiable with certainty and that were not all 
secured during the coiling procedure. In addition, intravenous nimodipine or intravenous nicardipine 
within 4 hours, or intravenous fasudil within 24 hours, before study drug initiation was not permitted.  
After coiling, patients were randomized (1:1:1) to receive intravenous clazosentan (5 or 15mg/h) or 
placebo for up to 14-days post-aSAH; the investigator completed a randomization form on an 
interactive, independent web response system, which assigned a randomization number for each 
patient according to a predefined scheme. Randomization was stratified by site. The randomization 
code was only available to authorized individuals with no involvement in study conduct or analysis 
until the time of unblinding.  
Sites were asked to manage patients according to guidelines developed for the study and consistent 
with published recommendations.6,8 Early detection and management of lung complications were also 
addressed. Drugs or procedures not considered standard care were prohibited. Oral, but not 
intravenous, nimodipine was permitted during the study.  
The study protocol was approved by local Institutional Review Boards and was completed in 
accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. 
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Assessments 
Prior to the coiling procedure, all patients underwent a CT scan and catheter or CT angiography at 
baseline. Additional CT scans were performed 24-48 hours after the coiling procedure (12 hours for 
sedated patients), at discharge (unless this occurred after the 6-week visit), 6 weeks after aSAH, and 
in cases of worsening neurological condition (also for cerebral angiograms) or DIND (also for cerebral 
angiograms). For cerebral angiograms, additional angiograms were performed after coiling to 
document the completeness of occlusion, or if symptoms suggestive of DIND. In sedated or otherwise 
unevaluable patients, an angiogram was performed at day 9±2. 
After treatment initiation, neurological assessments were performed every 6 hours until day 14 
(irrespective of study drug duration) using the modified Glasgow Coma Scale (mGCS) and the 
abbreviated National Institutes of Health Stroke Scale (NIHSS).9,10 Assessment of Glasgow Outcome 
Scale [extended version, GOSE]11 and modified Rankin Scale12 were carried out at week 12 by 
trained centralized interviewers via a structured telephone interview.  
All clinical and imaging data were reviewed by a centralized critical events committee (CEC). The 
CEC included an image review committee of neuroradiologists, who provided independent evaluation 
of CT scans and angiograms (each angiogram was reviewed by two neuroradiologists, with a third 
adjudicating if discrepancies occurred), and a clinical review committee (CRC) comprised of 
neurosurgeons and neurointensivists. The CRC made the final assessment regarding whether events 
were vasospasm-related and also gauged the contribution of angiographic vasospasm to poor clinical 
outcome (GOSE ≤4) at week 12. Individual components of the primary endpoint were evaluated by 
two neurosurgeons and one neurointensivist from the CRC; unanimity or consensus agreement was 
required. 
The primary efficacy endpoint assessed angiographic vasospasm-related morbidity and all-cause 
mortality within 6 weeks of aSAH, as defined by at least one of the following: death; vasospasm-
related cerebral infarction (where vasospasm was the primary cause or a relevant contributing factor); 
DIND due to vasospasm (where vasospasm was the primary cause or a relevant contributing factor) 
[DIND was a decrease of ≥2 mGCS points or an increase of ≥2 points on the abbreviated NIHSS 
lasting for ≥2 h. For patients under continuous sedation, DIND was defined as administration of valid 
rescue therapy, which included initiation or increase in dose of an intravenous vasopressor with or 
C-3 primary manuscript 
Page 5 
without fluid therapy, or intra-arterial vasodilator or balloon angioplasty]; or neurological signs or 
symptoms, in the presence of a positive angiogram, leading to rescue therapy. 
The main secondary endpoint was the GOSE, dichotomized as good [>4] or poor [≤4], at week 12. 
Additional secondary endpoints included occurrence of the individual components of the composite 
primary endpoint, and total volume of all new or worsened cerebral infarcts at week 6 post-aSAH. 
Planned supplementary analyses assessed the impact of subgroups (WFNS grade, clot size, age, 
and gender) on the primary and main secondary endpoint. Safety endpoints included death up to 
week 12 and treatment-emergent adverse events (AEs). 
Statistical analyses 
Assuming a RRR of 30% (odds ratio [OR]=0.603) with at least one dose of clazosentan (5 or 15mg/h) 
and a placebo event rate of 35%, it was calculated that with a total sample size of 1,470, a two-group 
continuity-corrected Chi-Square test had approximately 90% power to reject the null hypothesis 
(comparison-wise, two-sided, error rate of 2.5%).  
This trial was halted prematurely after non-significant results from the parallel CONSCIOUS-2 clipping 
study became apparent,7 and subsequent recommendations from the DSMB; as such, planned 
confirmatory analyses were not performed and formal testing of the global null hypothesis was not 
carried out. Treatment effect of the two clazosentan doses was tested in an exploratory manner using 
logistic regression adjusting for WFNS grade (≤II, >II) and described using OR with the corresponding 
95% confidence intervals (CIs). Dichotomized GOSE was analyzed using the same statistical 
methods as for the primary endpoint. In the case of a missing assessment for the morbidity 
component of the primary endpoint, or missing information on the vital status, the worst case (i.e., 
presence of vasospasm-related morbidity and mortality) was assumed. For GOSE, if no score was 
available, a score of 5 was assigned when there was no clinical evidence of prior neurological 
impairment, and a score of 3 given in any other situation when a patient was alive at week 12. 
Baseline demographics were analyzed using descriptive statistics; all values are mean and standard 
deviation (SD), or percent. 
Efficacy analyses were based on the full analysis set, defined as all treated patients (i.e., all those 
randomized who started infusion). Analysis of the primary outcome was also performed on the per-
C-3 primary manuscript 
Page 6 
protocol set, encompassing all patients without major protocol violations. Patients exposed to 
treatment, with at least one post-baseline safety measurement, were included in the safety dataset.  
Additional information on the rationale, study design and methodology has been published.13 
Results 
Baseline characteristics 
CONSCIOUS-3 was conducted between 10 July 2009 and 26 January 2011 (last patient, last visit) at 
106 centers in 27 countries; 577 of 1,470 patients (39% of the planned sample size) had been 
randomized at the time of study termination, and 571 (placebo n=189, clazosentan 5mg/h n=194, 
clazosentan 15mg/h n=188) had received treatment. Participant flow is shown in Figure 1. Adverse 
events were the most common reason for discontinuation of study drug in all arms; 
administrative/other reasons included stopping drug by mistake, early hospital discharge, and other 
technical/logistical reasons. Demographic and clinical characteristics were similar across all 
randomized groups at baseline (Table 1) and were characteristic of patients with aSAH. 
Patients received study treatment for a mean (SD) of 12 (2), 12 (3), and 12 (3) days in the placebo, 
clazosentan 5mg/h and 15mg/h groups, respectively, with treatment commencing 18 (12), 20 (12), 
and 18 (12) hours, respectively, after aneurysm coiling. Oral nimodipine was administered 
concomitantly to 94% (placebo), 95% (clazosentan 5mg/h), and 95% (clazosentan 15mg/h) of 
patients.  
Data for the primary endpoint were substituted for one patient with missing data in the clazosentan 
5mg/h group. For the GOSE secondary endpoint, four patients had data substituted in the placebo 
group (two with GOSE score 3; two with GOSE score 5), six patients had data substituted in the 
clazosentan 5mg/h group (six with GOSE score 3; none with GOSE score 5), and three patients had 
data substituted in the clazosentan 15mg/h group (two with GOSE score 3; one with GOSE score 5). 
Efficacy 
Vasospasm-related morbidity and all-cause mortality occurred in the all-treated population in 26% of 
patients in the placebo group compared with 24% and 15% in the 5 and 15mg/h clazosentan groups, 
respectively; a significant improvement was seen with 15mg/h clazosentan (RRR=44%; OR=0.474, 
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95% CI 28-82%; P=0.007), but not with 5mg/h (RRR=8%; OR=0.786, 95% CI 48-129%; P=0.340) 
(Figure 2a). In the per-protocol population, the event rates were 28% (placebo), 26% (clazosentan 
5mg/h; RRR=8%; OR=0.768, 95% CI 46-129%; P=0.321), and 15% (clazosentan 15mg/h; RRR=48%; 
OR=0.441, 95% CI 24-80%; P=0.007) of patients. Event rates in the all-treated population for each 
individual component of the composite endpoint are shown in Figure 2b; a higher proportion of 
patients required rescue therapy in the placebo group (21%) compared with clazosentan 5mg/h (15%) 
and 15mg/h (7%). 
Poor functional outcome (GOSE score ≤4; endpoint substituted) occurred in 24% of patients in the all-
treated placebo group compared with 25% (RRR=4%; OR=0.918, 95% CI 55-154%; P=0.748) and 
28% (RRR=14%; OR=1.337, 95% CI 80-223%; P=0.266) in the clazosentan 5 and 15mg/h groups, 
respectively. 
In the placebo group, the CEC-confirmed new cerebral infarct mean total volume at week 6 post-
aSAH was 50.40 cm3 compared with the clazosentan 5mg/h and 15mg/h groups (40.74 cm3 and 
59.03 cm3, respectively). 
Results from planned subgroup analyses of vasospasm-related morbidity and all cause mortality, and 
occurrence of poor GOSE outcome, according to sex, age, baseline clot size, and WFNS grade at 
baseline are shown in Figures 3 and 4. 
Safety and tolerability 
During the study, 91%, 86%, and 92% of patients receiving placebo, clazosentan 5 and 15mg/h, 
respectively, experienced ≥1 AE. The most commonly-reported AEs were pyrexia (23%, 22%, and 
26%), constipation (21%, 22%, and 22%), and cerebrovascular spasm (32%, 22%, and 14%) in the 
placebo, clazosentan 5 and 15mg/h groups, respectively. Severe AE incidence was 25% (placebo) 
28% (clazosentan 5mg/h), and 29% (clazosentan 15mg/h); rates of AEs considered by the 
investigator to be related to treatment was 24%, 34%, and 37%, respectively. Incidence of AEs of 
specific interest is shown in Table 2. 
Of treated patients, 6% (placebo), 4% (clazosentan 5mg/h), and 6% (clazosentan 15mg/h) died within 
12 weeks of aSAH; causes of death reported for >1% of patients in any group were cerebral infarction 
(2%, <1%, and 3%), cerebrovascular spasm (2%, <1%, and <1%), and brain edema (2%, <1%, and 
<1%), respectively. 
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Discussion 
This randomized, double-blind, placebo-controlled, phase III trial investigated outcomes with 
clazosentan 5 or 15mg/h administered for up to 14 days in patients with aSAH secured by 
endovascular coiling. The trial was halted early due to non-significant findings with clazosentan 5mg/h 
in the parallel CONSCIOUS-2 clipping study.7 For the lower dose, data from the present study support 
findings from CONSCIOUS-2, i.e. clazosentan 5mg/h had no significant effect on vasospasm-related 
morbidity or all-cause mortality 6-weeks post-aSAH (composite primary endpoint) or functional 
outcome. Nonetheless, the main objective of demonstrating that at least one dose (5 or 15mg/h) of 
clazosentan reduces vasospasm-related morbidity or all-cause mortality within 6-weeks post-aSAH 
was met: a statistically significant treatment effect of clazosentan 15mg/h was observed for the 
primary endpoint. The reduction in the primary endpoint event rate did not translate into improved 
functional outcomes at week 12, as measured by GOSE. However, the effect of 15mg/h clazosentan 
on vasospasm-related morbidity events provides further support for a dose-related effect on the 
occurrence of cerebrovascular spasm post-aSAH as observed in the phase IIb CONSCIOUS-1 study 
where the 15mg/h clazosentan dose significantly reduced mortality and vasospasm-related morbidity.6 
Some explanations for the lack of effect of the 5mg/h clazosentan dose have been documented.7 
Reasons include the possibility that the tolerability profile of the drug negated therapeutic benefit or 
that interaction with oral nimodipine contributed to AEs. Rescue therapy may provide a positive effect 
on outcome that obscures the benefit of clazosentan. Other factors may also contribute to poor 
outcome that are not treated by clazosentan. Interestingly, the causes of death/AEs in the placebo 
group related to vasospasm were higher than in the clazosentan groups, while non-vasospasm 
related causes were higher in the clazosentan groups. Additionally, the GOSE may not detect 
meaningful improvements in outcome. Central assessment of the primary endpoint, which ensured 
the specificity was high, could have decreased the sensitivity by excluding questionable events.  
In the present study, which investigated 15mg/h clazosentan as well as 5mg/h, the higher dose 
reduced vasospasm-related morbidity or all-cause mortality within 6-weeks post-aSAH, but did not 
improve functional outcomes. If it is assumed that rescue therapy prevents the ischemic 
consequences of vasospasm on long term clinical outcome, the three-fold more frequent use of 
rescue therapy in the 15mg/h group compared with the placebo arm could have accounted for the 
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lack of treatment effect observed on GOSE. Due to the early stopping of this trial, the planned number 
of patients was not enrolled, therefore, it cannot be ruled out that low statistical power may explain the 
lack of effect observed with 5mg/h clazosentan. Preplanned subgroup analyses of the primary 
endpoint and dichotomized GOSE scores did not reveal an obvious explanation for the outcome of 
this study. For future trials, investigating different durations of clazosentan administration could be 
considered.14,15  
A higher proportion of patients receiving clazosentan (5 mg/h and 15 mg/h) prematurely discontinued 
treatment compared with the placebo group; the main reason for discontinuation from study drug was 
AEs. The AEs (lung complications, hypotension, and anemia) experienced by the patients in this 
study were consistent with those observed in CONSCIOUS-1 and CONSCIOUS-2, suggesting no 
new safety concerns. An equal proportion of patients in the clazosentan 15mg/h and placebo groups 
died during the study, with cerebral infarction the most frequently-reported primary cause of death in 
these groups. 
Summary 
Clazosentan at 15mg/h reduced cerebral vasospasm-related morbidity and all-cause mortality; 
however, the effect with clazosentan 5mg/h was not significant. Neither dose improved functional 
outcome as measured by GOSE, possibly due to greater use of rescue therapy in the placebo group. 
Compared with placebo, pulmonary complications, anemia, and hypotension were more common in 
patients receiving clazosentan, particularly with the higher dose; however, no new safety concerns 
were observed. 
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Figures 
[Note that the figures presented below will be redrawn according to the journal style and author preferences prior to manuscript submission] 
Figure 1: Participant flow.  
 
aSAH: aneurysmal subarachnoid hemorrhage; GOSE: extended Glasgow Outcome Scale; WFNS: World Federation of Neurological Surgeons. 
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Figure 2: Event rate (%) for: a) all cause mortality and vasospasm-related morbidity at 6 weeks 
(all-treated, endpoint substituted); and b) each of the individual components of the primary 




























Odds Ratio: 0.786 
(95% CI: 0.479–1.289)
P=0.3395a


































































aAdjusted by WFNS, logistic regression 
RRR: relative risk reduction; CI: confidence interval; DIND: delayed ischemic neurological deficit 
C-3 primary manuscript 
Page 16 
Figure 3. Effect of a) sex, b) age, c) baseline clot size, and d) WFNS grade at baseline on 
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WFNS: World Federation of Neurological Surgeons 
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Figure 4. Effect of a) sex, b) age, c) baseline clot size, and d) WFNS grade at baseline on 
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WFNS: World Federation of Neurological Surgeons 
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Tables 















Male 55 (29) 59 (30) 58 (31) 172 (30) 
Mean (SD) age, years  54 (11) 52 (11) 53.6 (11) 53.1 (11) 
Age range, years 23-75 23-75 19-76 19-76 
WFNS admission grade      
Grade I 96 (51)  99 (51) 103 (55) 298 (53) 
Grade II 56 (30)  48 (25) 53 (28) 157 (28) 
Grade III 6 (3)  5 (3) 3 (2) 14 (3) 
Grade IV 24 (13)  37 (19) 26 (14) 87 (15) 
Grade V 5 (3)  4 (2) 2 (1) 11 (2) 
Motor deficit present at admission  19 (10)  21 (11) 18 (10) 58 (10) 
Number of aneurysms secured (ruptured and unruptured) 
1 183 (97) 183 (94) 177 (94) 543 (95) 
2 6 (3) 10 (5) 10 (5) 26 (5) 
>2 0 1 (<1) 1 (<1) 2 (<1) 
Size of clipped ruptured aneurysm 
≤15 mm 183 (98) 193 (100) 181 (97) 557 (98) 
>15 mm 5 (3) 1 (<1) 6 (3) 12 (2) 
Key locations of ruptured aneurysms 
Supraclinoid ICA 19 (10)  22 (11)  31 (17)  72 (13)  
MCA  16 (9)  19 (10)  23 (12)  58 (10) 
ACA  10 (5)  21 (11)  13 (7)  44 (8) 
ACoA  74 (39)  62 (32)  62 (33)  198 (35) 
PCoA  31 (16)  39 (20)  35 (19)  105 (18) 
Distal VA  11 (6)  5 (3)  8 (4)  24 (4) 















Basilar artery  22 (12)  22 (11)  15 (8)  59 (10) 
Clot size at baseline     
Diffuse thick  116 (61)  118 (61)  111 (59)  345 (61)  
Local thick  58 (31)  54 (28)  56 (30)  168 (30)  
Diffuse thin  12 (6)  17 (9)  17 (9)  46 (8)  
Local thin  3 (2) 2 (1) 4 (2)  9 (2) 
Unable to assess  0 2 (1)  0 2 (<1) 
 
Values are n (%) unless otherwise stated 
ACA: anterior cerebral artery; ACoA: anterior communicating aneurysm; ICA: internal carotid artery; MCA: middle 
cerebral artery; PCoA: posterior communicating artery; WFNS: World Federation of Neurological Surgeons. 
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Table 2. Adverse events of specific interest occurring up to 1 day after study drug 
discontinuation and up to week 6 post aSAH (safety population). 
Grouping of MedDRA terms;  






5 mg/h  
n=194 
Clazosentan 
15 mg/h  
n=188 
Lung complications  40 (21)  70 (36)  70 (37)  
Lung complications related to pulmonary edema 16 (9) 37 (19) 32 (17) 
Hypotension  13 (7)  21 (11)  30 (16)  
Hepatobiliary events 35 (19) 39 (20) 28 (15) 
Anemia  18 (10)  25 (13)  24 (13)  
Rhythm/conduction disorders  23 (12)  16 (8)  20 (11)  
Cerebral hemorrhage  5 (3  7 (4  7 (4)  
Cardiac ischemic events  3 (2)  8 (4)  6 (3)  
Eye disorders  0 0 6 (3)  
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